Abcellera Biologics Inc
ABCL4.170USD
-0.050-1.18%
收盤 09/08, 16:00（美東）報價延遲15分鐘
1.25B總市值
虧損本益比TTM
關於 Abcellera Biologics Inc 公司
AbCellera Biologics Inc. 發現和開發用於治療癌症、代謝和內分泌疾病以及自身免疫性疾病等治療領域的抗體藥物。該公司的引擎整合了技術、數據科學、基礎設施和跨學科團隊，以解決抗體發現問題。該公司已經開發了技術平臺來解鎖藥物類別、靶點和模式，包括跨膜蛋白、T 細胞接合劑和肽-MHC。該公司專注於推進內部項目管線並與合作伙伴合作開展藥物開發項目。其內部管線中的前兩個臨牀前項目是 ABCL575 和 ABCL635。ABCL635 是一種針對未公開靶點的抗體藥物候選物，適用於代謝和內分泌疾病。ABCL575 靶向 OX40 配體，正在開發用於治療特應性皮炎和其他自身免疫和炎症適應症的療法。
公司簡介
公司代碼ABCL
公司名稱Abcellera Biologics Inc
上市日期Dec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
員工數量596
證券類型Ordinary Share
年結日Dec 11
公司地址150 W 4Th Avenue
城市VANCOUVER
上市交易所NASDAQ Global Select Consolidated
國家Canada
郵編V5Y 1G6
電話16045599005
網址https://www.abcellera.com/
公司代碼ABCL
上市日期Dec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
收入明細
單位: USD更新時間: 2月22日 週六
單位: USD更新時間: 2月22日 週六
FY2024Q2
FY2023Q2
業務USD
名稱
營收
佔比
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
其他
60.85%
持股股東
持股股東
佔比
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
其他
60.85%
股東類型
持股股東
佔比
Corporation
18.79%
Hedge Fund
16.22%
Investment Advisor
15.65%
Individual Investor
4.15%
Investment Advisor/Hedge Fund
2.99%
Bank and Trust
1.20%
Private Equity
1.13%
Research Firm
0.63%
Venture Capital
0.32%
其他
38.92%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
372
214.57M
71.89%
-123.81K
2025Q1
429
202.31M
67.85%
-22.54M
2024Q4
453
194.86M
65.41%
-21.40M
2024Q3
451
190.45M
64.55%
-29.37M
2024Q2
449
195.17M
66.27%
-23.48M
2024Q1
442
202.34M
69.21%
-22.49M
2023Q4
434
206.18M
71.07%
-38.61M
2023Q3
437
216.53M
74.89%
-39.50M
2023Q2
439
222.03M
76.83%
-29.38M
2023Q1
423
223.82M
78.22%
-38.92M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Thermopylae Holdings Ltd
56.14M
18.81%
--
--
Apr 01, 2025
Baker Bros. Advisors LP
27.53M
9.22%
--
--
Mar 31, 2025
Capital World Investors
13.36M
4.48%
+5.43M
+68.41%
Mar 31, 2025
Baillie Gifford & Co.
11.20M
3.75%
-1.04M
-8.50%
Mar 31, 2025
Lecault (Veronique)
9.61M
3.22%
--
--
Apr 01, 2025
Two Sigma Investments, LP
5.77M
1.93%
-94.12K
-1.60%
Mar 31, 2025
UBS Asset Management (Americas) LLC
6.61M
2.21%
+6.61M
--
Mar 31, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.38%
--
--
Mar 31, 2025
UBS Asset Management (Switzerland)
9.06M
3.04%
+4.56M
+101.35%
Mar 31, 2025
UBS Switzerland AG
5.05M
1.69%
+4.91M
+3556.81%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月6日 週三
更新時間: 8月6日 週三
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
1.77%
TrueShares Technology, AI & Deep Learning ETF
1.53%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
Invesco Nasdaq Biotechnology ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.1%
SPDR S&P International Small Cap ETF
0.07%
Invesco RAFI Developed Mkts ex-US SM ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比1.77%
TrueShares Technology, AI & Deep Learning ETF
佔比1.53%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.98%
Invesco Nasdaq Biotechnology ETF
佔比0.13%
ProShares Ultra Nasdaq Biotechnology
佔比0.11%
iShares Biotechnology ETF
佔比0.1%
SPDR S&P International Small Cap ETF
佔比0.07%
Invesco RAFI Developed Mkts ex-US SM ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.01%
SPDR Portfolio Developed World ex-US ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
